Hereditary Hemorrhagic Telangiectasia (HHT) Center

HHS-HRSA Posted HRSA-26-092

Description

The purpose of the Hereditary Hemorrhagic Telangiectasia (HHT) Center Program is to reduce illness and death related to HHT by partnering with clinical center to expand access and coordination of care; creating innovative strategies that support clinicians with identifying and diagnosing HHT cases; and developing a de-identified, aggregate patient data registry to better understand this rare disease and its treatment outcomes.

Eligibility

"Domestic" means the 50 states, the District of Columbia, the Commonwealth of Puerto Rico, the Northern Mariana Islands, American Samoa, Guam, the U.S. Virgin Islands, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau.
Funding Details
Award Floor
Not specified
Award Ceiling
$2,900,000.00
Total Estimated Funding
$2,900,000.00
Expected Awards
1
Key Dates
Posted
June 8, 2026
Closes
July 10, 2026
Archive Date
August 30, 2026
Agency Information
Agency Name
Health Resources and Services Administration
Agency Code
HHS-HRSA
Funding Instrument
Other